Squarepoint
LBRX icon

Squarepoint’s LB Pharmaceuticals LBRX Stock Holding History

Squarepoint’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$999K Buy
+26,018
New +$1.08M ﹤0.01% 2779
2025
Q4 		– Sell
-20,825
Closed -$329K – 5055
2025
Q3 		$329K Buy
+20,825
New +$330K ﹤0.01% 3595

Other funds holding LBRX

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint's LBRX Position: Q3 2026 in Review

Squarepoint opened a new position in LB Pharmaceuticals (LBRX) in Q3 2026: 26,018 shares worth $999K. The stake represents ﹤0.01% of the portfolio and ranks #2779 among its holdings. This is a return to the name: Squarepoint previously reported a position in LBRX as recently as Q3 2025.

Squarepoint first reported a position in LBRX in Q3 2025 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

  • Squarepoint held 26,018 shares of LB Pharmaceuticals worth $999K as of Q3 2026.
  • LB Pharmaceuticals was a new Squarepoint position in Q3 2026.
  • LB Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2779 holding.
  • Squarepoint first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.